

01-10-02

Box 509 A

PTO/SB/05 (03-01)

Approved for use through 10/31/2002 OMB 0651-0032

U S Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Please type a plus sign (+) inside this box →

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR

Attorney Docket No.

LEX-0294-USA

First Inventor

Hu

Title Novel Human Protease and Polynucleotides Encoding the Same

Express Mail Label No.

EL 893393587 US

153 (b)(1)

J1000 U.S. PATENT & TRADEMARK OFFICE
01/08/02**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application

1. Fee Transmittal Form (e.g., PTO/SB/17)**ADDRESS TO:**Assistant Commissioner for Patents
Box Patent Application
Washington, DC 202312. Applicant claims small entity status.
See 37 CFR 1.27.7. CD-ROM or CD-R in duplicate, large table or
Computer Program (Appendix)3. Specification [Total Pages 33]8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- Descriptive title of the Invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Description of the Invention (if filed)
- Detailed Description
- Claim(s)
- Abstract of the disclosure

a. Computer Readable Form (CRF) on diskette4. Drawing(s)(35 U.S.C.113) [Total Sheets]

b. Specification Sequence Listing on:

- i. CD-ROM or CD-R (2 copies); or
- ii. paper (5 pages)

5. Oath or Declaration [Total Pages 2]

c. Statements verifying identity of above copiesa. Unexecuted (original or copy)**ACCOMPANYING APPLICATION PARTS**b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)9. Assignment Papers (cover sheet & document(s))i. **DELETION OF INVENTOR(S)**
signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).10. 37 CFR 3.73(b) Statement
(when there is an assignee) Power of Attorney6. Application Data Sheet. See 37 CFR 1.7611. English Translation Document (if applicable)

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____13. Preliminary Amendment14. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)16. Nonpublication Request under 35 U.S.C. 122, (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent17. Other: _____Prior application information: Examiner _____ Group Art Unit: _____
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.**19. CORRESPONDENCE ADDRESS**

(Insert Customer No. or Attach bar code label here)

 Customer Number or Bar Code Labelor Correspondence address below

Name

24231

PATENT TRADEMARK OFFICE

Address

City

State

Zip

Country

Telephon

Fax

Name (Print/Type)

Lance K. Ishimoto

Registration No. (Attorney/Agent)

41,866

DAVID W. HABER REC. NO. 41,071

Signature

Lance K. Ishimoto by David W. Haber

Date

January 8, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$)

Complete if Known	
Application Number	Not Yet Assigned
Filing Date	1/8/2002
First Named Inventor	Hu et al.
Examiner Name	Not Yet Assigned
Group Art Unit	Not Yet Assigned

Attorney Docket No. LEX-0294-USA

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None
 Deposit Account

Deposit Account Number 50-0892
Deposit Account Name _____

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee
to the above-identified deposit account

FEE CALCULATION

1. BASIC FILING FEE

Large Entity | Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	370.00
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) (\$ 370.00)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent	-2**=	X _____	= _____
Multiple Dependent	-3***=	X _____	= _____

Large Entity | Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

3. ADDITIONAL FEES			
Large Entity		Small Entity	
Fee Code	Fee (\$)	Fee Code	Fee (\$)
105	130	205	65
127	50	227	25
139	130	139	130
147	2,520	147	2,520
112	920*	112	920*
113	1,840*	113	1,840**
115	110	215	55
116	400	216	200
117	920	217	460
118	1,440	218	720
128	1,960	228	980
119	320	219	160
120	320	220	160
121	280	221	140
138	1,510	138	1,510
140	110	240	55
141	1,280	241	640
142	1,280	242	640
143	460	243	230
144	620	244	310
122	130	122	130
123	50	123	50
126	180	126	180
581	40	581	40
146	740	246	370
149	740	249	370
179	740	279	370
169	900	169	900
Other fee (specify) _____			

SUBTOTAL (3) (\$)

*Reduced by Basic Filing Fee Paid

SUBMITTED BY					
Complete (if applicable)					
Name (Print/Type)	Lance K. Ishimoto Lexicon Genetics Incorporated	Registration No (Attorney/Agent)	41,866	Telephone	281-863-3333
Signature	Lance K. Ishimoto by David W. Houser DAVID W. Houser FEB. NO. 41, 071				
	Date	January 8, 2002			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization of PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Hu et al.

U.S. Ser. No.: To be assigned Attorney Docket No.: LEX-0294-USA

Filing Date: January 8, 2002

For: Novel Human Protease and
Polynucleotides Encoding the Same

VERIFIED STATEMENT

Box Patent Application
Commission for Patents
Washington, D.C. 20231

Sir:

I, DRENDA D. THOMAS, do declare and state as follows:

1. I prepared a Sequence Listing in paper and computer readable form under 37 C.F.R. Sec. 1.821-1.825 in connection with the above-captioned patent application, both of which are being submitted herewith.

2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same.

Signed,



Drenda D. Thomas

January 8, 2002
Date